Name: Terns Pharmaceuticals, Inc. (TERN) Financial Statements
Creator: FinSpry

Terns Pharmaceuticals Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Terns Pharmaceuticals, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	0.00	0.00	0.00	1.00	0.00
Cost of Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	1.00	0.00
Operating Expenses
Research & Development	70.11	63.50	39.62	31.31	28.03
Selling, General & Administrative	31.76	39.06	22.41	19.55	9.00
Operating Expenses	101.87	102.56	62.03	50.86	37.03
Operating Income	-101.87	-102.56	-62.03	-49.86	-37.03
Other Income/Expense
Interest Income	13.29	12.90	2.11	0.17	0.06
Interest Expense	0.00	0.00	0.00	0.00	0.00
Other Income/Expense	13.28	-0.31	-0.07	0.04	-2.79
Income
Income Before Tax	-88.59	-89.97	-59.99	-49.65	-39.76
Income Tax Expense	0.26	0.24	0.36	0.51	0.81
Net Income	-88.85	-90.21	-60.35	-50.16	-40.05
Net Income - Continuous Operations	-88.85	-90.21	-60.35	-50.16	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	-100.98	-102.27	-61.55	-49.35	-36.63
EBIT	-88.59	-102.56	-62.03	-49.86	-37.03
Depreciation & Amortization	0.90	0.29	0.48	0.51	0.39
Earnings Per Share
Basic EPS	-1.00	-1.00	-2.00	-2.00	-1.00
Diluted EPS	-1.00	-1.00	-2.00	-2.00	-1.00
Basic Shares Outstanding	79.51	71.26	36.03	22.71	22.72
Diluted Shares Outstanding	79.51	71.26	36.03	22.71	22.72